Atlas Trials

Trial Ruxolitinib and Peg-interferon Alpha-2a Combination in Patients With Primary Myelofibrosis RUXOPeg

Clinical trial NCT02742324 · COMPLETED

Trial details

NCT number
NCT02742324
Sponsor
French Innovative Leukemia Organisation
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Myelofibrosis
Start date
2016-03-01
Primary completion
2021-12-30
Enrollment
37

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.